99 related articles for article (PubMed ID: 21742829)
1. Population effectiveness, not efficacy, should decide who gets vaccinated against human papillomavirus via publicly funded programs.
Castle PE; Zhao FH
J Infect Dis; 2011 Aug; 204(3):335-7. PubMed ID: 21742829
[No Abstract] [Full Text] [Related]
2. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity.
Brisson M; van de Velde N; Franco EL; Drolet M; Boily MC
J Infect Dis; 2011 Aug; 204(3):372-6. PubMed ID: 21742835
[TBL] [Abstract][Full Text] [Related]
3. A brief history of economic evaluation for human papillomavirus vaccination policy.
Beutels P; Jit M
Sex Health; 2010 Sep; 7(3):352-8. PubMed ID: 20719227
[TBL] [Abstract][Full Text] [Related]
4. Prevention strategies against the human papillomavirus: the effectiveness of vaccination.
Stanley M
Gynecol Oncol; 2007 Nov; 107(2 Suppl 1):S19-23. PubMed ID: 17938013
[TBL] [Abstract][Full Text] [Related]
5. [Shortsighted economics behind the choice of HPV vaccine. Sweden misses the chance the chance "to eradicate" condyloma].
Rylander E
Lakartidningen; 2010 Jun 30-Jul 20; 107(26-28):1688-9. PubMed ID: 20701147
[No Abstract] [Full Text] [Related]
6. Response to: Demarteau N, Standaert B. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 2010;13:324-38.
Hillemanns P
J Med Econ; 2011; 14(2):262-6. PubMed ID: 21385146
[No Abstract] [Full Text] [Related]
7. Cost–effectiveness of catch-up programs in human papillomavirus vaccination.
de Peuter MA; Littlewood KJ; Annemans L; Largeron N; Quilici S
Expert Rev Vaccines; 2010 Oct; 9(10):1187-201. PubMed ID: 20923269
[TBL] [Abstract][Full Text] [Related]
8. Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.
Demarteau N; Standaert B
J Med Econ; 2010; 13(2):324-38. PubMed ID: 20504110
[TBL] [Abstract][Full Text] [Related]
9. [Prevention of HPV-associated neoplasias by vaccination - short version of the German S3 (level 3) guideline].
Gross G; Gissmann L; Hillemanns P; Ikenberg H; Kaufmann AM; Petry KU; Pfister H; Schneede P; Schneider A; Smola S;
Dtsch Med Wochenschr; 2010 May; 135(21):1083-6. PubMed ID: 20486060
[No Abstract] [Full Text] [Related]
10. Start early to prevent genital HPV infection-and cervical cancer.
Heavey E
Nursing; 2008 May; 38(5):62-3. PubMed ID: 18431214
[No Abstract] [Full Text] [Related]
11. Greatest effect of HPV vaccination from school-based programmes.
Regan DG; Hocking JS
Lancet Infect Dis; 2015 May; 15(5):497-8. PubMed ID: 25744473
[No Abstract] [Full Text] [Related]
12. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine.
Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911
[TBL] [Abstract][Full Text] [Related]
13. The quadrivalent human papillomavirus vaccine.
Wheat A
Med Health R I; 2008 Dec; 91(12):387-9. PubMed ID: 19170317
[No Abstract] [Full Text] [Related]
14. Prophylactic vaccines for human papillomavirus: a bright future for cervical cancer prevention.
Szarewski A
J Med Screen; 2005; 12(4):163-5. PubMed ID: 16417690
[No Abstract] [Full Text] [Related]
15. Quadrivalent HPV vaccine. Wider cost benefits of vaccine.
O'Mahony C; Greenhouse P; Robinson A; Sonnex C
BMJ; 2010 Aug; 341():c4455. PubMed ID: 20724414
[No Abstract] [Full Text] [Related]
16. HPV/cervical cancer vaccination: parental preferences on age, place and information needs.
Rose SB; Lawton BA; Lanumata T; Hibma M; Baker MG
J Prim Health Care; 2010 Sep; 2(3):190-8. PubMed ID: 21069114
[TBL] [Abstract][Full Text] [Related]
17. The new human papillomavirus (HPV) vaccine: pros and cons for pediatric and adolescent health.
Thomas TL
Pediatr Nurs; 2008; 34(5):429-31. PubMed ID: 19051848
[TBL] [Abstract][Full Text] [Related]
18. Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.
Pitts MK; Heywood W; Ryall R; Smith AM; Shelley JM; Richters J; Simpson JM
Sex Health; 2010 Sep; 7(3):299-303. PubMed ID: 20719218
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus vaccination: stabbing in the dark?
Leyland E
Lancet; 2008 Aug; 372(9639):614. PubMed ID: 18722854
[No Abstract] [Full Text] [Related]
20. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses.
Westra TA; Rozenbaum MH; Rogoza RM; Nijman HW; Daemen T; Postma MJ; Wilschut JC
J Infect Dis; 2011 Aug; 204(3):377-84. PubMed ID: 21742836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
